

order to facilitate their entry into the building. Contact Ann Ferrero using the information mentioned above by Thursday, October 18, 2018, 12:00 p.m. ET. All attendees are required to present government-issued identification prior to entry. The meeting will also be accessible via webcast. Instructions on how to access the meeting via webcast will be provided upon registration.

**Amy P. McNulty,**

*Acting Director, Division of the Executive Secretariat.*

[FR Doc. 2018-20428 Filed 9-19-18; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Institute Council of Research Advocates.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (<http://videocast.nih.gov>).

*Name of Committee:* National Cancer Institute Council of Research Advocates.

*Date:* October 19, 2018.

*Time:* 9:00 a.m. to 4:30 p.m.

*Agenda:* Welcome and Chairman's Remarks, NCI Updates, Legislative Update, Budget Update, and Director's Update.

*Place:* National Institutes of Health, 35A Convent Drive, Building 35A, 640, Bethesda, MD 20892.

*Contact Person:* Amy Williams, NCI Office of Advocacy Relations, National Cancer Institute, NIH, 31 Center Drive, Building 31, Room 10A28, Bethesda, MD 20892, 240-781-3360 [williaam@mail.nih.gov](mailto:williaam@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a

government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: NCRA: <http://deainfo.nci.nih.gov/advisory/ncra/ncra.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: September 14, 2018.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2018-20418 Filed 9-19-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:**

Barry Buchbinder, Ph.D., 240-627-3678; [barry.buchbinder@nih.gov](mailto:barry.buchbinder@nih.gov).

Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

**SUPPLEMENTARY INFORMATION:**

Technology description follows.

#### Glycan-Masked Engineered Outer Domains of HIV-1 GP120 and Their Use

*Description of Technology:*

The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has been a major target of HIV-vaccine design. The current best priming immunogen to engage the VRC01-class germline precursors is the eOD-GT8 60mer, which elicits VRC01-class precursors in multiple transgenic mouse models. However, a large proportion of the antibodies elicited by eOD-GT8 60mer are non-CD4bs or "off-target" antibodies, undermining its effectiveness in eliciting the VRC01-class bnAb precursors.

Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases introduced multiple N-linked glycosylation sites to mask non-CD4bs regions of eOD-GT8 60mer to focus the antibody immune response to the CD4bs.

Several glycan-masked mutants showed significantly decreased antibody binding to non-CD4bs "off-target" epitopes while maintaining strong binding to CD4bs-specific bnAbs. Furthermore, in vivo studies showed that immunization with the best glycan-masked eOD-GT8 mutants resulted in significant increases in the elicitation of CD4bs-specific serum antibodies, CD4bs-specific B cells in the spleen, and VRC01-class precursors, compared to immunization with the parental eOD-GT8 immunogen. In conclusion, because of their improved antigenic and immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as improved priming immunogens to elicit VRC01-class bnAbs in humans.

*Potential Commercial Applications:*

- HIV-1 vaccine—the priming component in a prime-boost approach.

*Competitive Advantages:*

- Reduced off-target immunogenicity.
- Improved efficacy in eliciting precursors for broadly neutralizing CD4bs antibodies.

- Facilitates the development of VRC01-class bnAbs in humans.

*Development Stage:* In vivo testing (rodents).

*Inventors:* John R. Mascola (NIAID), Hongying Duan (NIAID), Xuejun Chen (NIAID), Cheng Cheng (NIAID) and Jeffrey C. Boyington (NIAID).

*Publications:* Duan, H. et al., Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. *Immunity* 49, 301 (2018).

*Intellectual Property:* HHS Reference Number E-083-2017 includes U.S. Provisional Patent Application Number 62/476,397 filed 03/24/2017 and PCT

Application Number PCT/US2018/  
024330 filed 03/26/2018.

*Licensing Contact:* Barry Buchbinder,  
Ph.D., 240-627-3678;  
[barry.buchbinder@nih.gov](mailto:barry.buchbinder@nih.gov).

Dated: September 10, 2018.

**Suzanne M. Frisbie,**

*Deputy Director, Technology Transfer and  
Intellectual Property Office, National Institute  
of Allergy and Infectious Diseases.*

[FR Doc. 2018-20484 Filed 9-19-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

Pursuant to section 10(d) of the  
Federal Advisory Committee Act, as  
amended, notice is hereby given of the  
following meetings.

The meetings will be closed to the  
public in accordance with the  
provisions set forth in section  
552b(c)(6), Title 5 U.S.C., as amended.  
The grant applications and the  
discussions could disclose confidential  
trade secrets or commercial property  
such as patentable material, and  
personal information concerning  
individuals associated with the grant  
applications, the disclosure of which  
would constitute a clearly unwarranted  
invasion of personal privacy.

*Name of Committee:* National Institute of  
Dental and Craniofacial Research Special  
Emphasis Panel; DPBRN ARC.

*Date:* November 14, 2018.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant  
applications.

*Place:* Hilton Garden Inn, 7301 Waverly  
Street, Bethesda, MD 20814.

*Contact Person:* Guo He Zhang, MPH,  
Ph.D., Scientific Review Officer, Scientific  
Review Branch, National Institute of Dental  
and Craniofacial Research, National Institutes  
of Health, 6701 Democracy Boulevard, Suite  
672, Bethesda, MD 20892, [zhanggu@mail.nih.gov](mailto:zhanggu@mail.nih.gov).

*Name of Committee:* National Institute of  
Dental and Craniofacial Research Special  
Emphasis Panel; DPBRN Coordinating  
Center.

*Date:* November 14, 2018.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant  
applications.

*Place:* Hilton Garden Inn Bethesda, 7301  
Waverly Street, Bethesda, MD 20814.

*Contact Person:* Guo He Zhang, MPH,  
Ph.D., Scientific Review Officer, Scientific  
Review Branch, National Institute of Dental  
and Craniofacial Research, National Institutes  
of Health, 6701 Democracy Boulevard, Suite

672, Bethesda, MD 20892, [zhanggu@mail.nih.gov](mailto:zhanggu@mail.nih.gov).

(Catalogue of Federal Domestic Assistance  
Program Nos. 93.121, Oral Diseases and  
Disorders Research, National Institutes of  
Health, HHS)

Dated: September 14, 2018.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2018-20424 Filed 9-19-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the  
Federal Advisory Committee Act, as  
amended, notice is hereby given of the  
following meeting.

The meeting will be closed to the  
public in accordance with the  
provisions set forth in sections  
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,  
as amended. The grant applications and  
the discussions could disclose  
confidential trade secrets or commercial  
property such as patentable material,  
and personal information concerning  
individuals associated with the grant  
applications, the disclosure of which  
would constitute a clearly unwarranted  
invasion of personal privacy.

*Name of Committee:* National Institute of  
Allergy and Infectious Diseases Special  
Emphasis Panel Centers of Excellence for  
Translational Research (CETR) (U19).

*Date:* October 11-12, 2018.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant  
applications.

*Place:* Doubletree Hotel Bethesda,  
(Formerly Holiday Inn Select), 8120  
Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Yong Gao, Ph.D., Scientific  
Review Officer Scientific Review Program,  
Division of Extramural Activities, Room  
#3G13B, National Institutes of Health/NIAID,  
5601 Fishers Lane, MSC 9823, Rockville, MD  
20892-7616, (240) 669-5048, [yong.gao@nih.gov](mailto:yong.gao@nih.gov).

(Catalogue of Federal Domestic Assistance  
Program Nos. 93.855, Allergy, Immunology,  
and Transplantation Research; 93.856,  
Microbiology and Infectious Diseases  
Research, National Institutes of Health, HHS)

Dated: September 14, 2018.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2018-20421 Filed 9-19-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in  
the meeting of the Molecular Genetics B  
Study Section, September 27, 2018,  
10:00 a.m. to September 28, 2018, 06:00  
p.m., National Institutes of Health, 6701  
Rockledge Drive, Bethesda, MD, 20892  
which was published in the **Federal  
Register** on September 06, 2018,  
83FR173 pg. 45264.

The meeting will be held on  
September 27, 2018, starting at 8:30 a.m.  
The meeting location remains the same.  
The meeting is closed to the public.

Dated: September 14, 2018.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2018-20415 Filed 9-19-18; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the  
Federal Advisory Committee Act, as  
amended, notice is hereby given of the  
following meetings.

The meetings will be closed to the  
public in accordance with the  
provisions set forth in sections  
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,  
as amended. The grant applications and  
the discussions could disclose  
confidential trade secrets or commercial  
property such as patentable material,  
and personal information concerning  
individuals associated with the grant  
applications, the disclosure of which  
would constitute a clearly unwarranted  
invasion of personal privacy.

*Name of Committee:* Brain Disorders and  
Clinical Neuroscience Integrated Review  
Group; Clinical Neuroscience and  
Neurodegeneration Study Section.

*Date:* October 3-4, 2018.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant  
applications.

*Place:* National Institutes of Health, 6701  
Rockledge Drive, Bethesda, MD 20892.

*Contact Person:* Alessandra C. Rovescalli,  
Ph.D., Scientific Review Officer, National  
Institutes of Health, Center for Scientific  
Review, 6701 Rockledge Drive, Rm 5205  
MSC7846, Bethesda, MD 20892, (301) 435-  
1021, [rovescalla@mail.nih.gov](mailto:rovescalla@mail.nih.gov).